FDA Removes Black Box Warnings From Menopause Hormone Therapy

Opposition narrative

Removing the black box warnings on hormone replacement therapy (HRT) could increase access to hormone therapy for women experiencing menopausal symptoms, and this change is welcomed by most experts. However, like all medications, systemic estrogen products are not without risk. It is important not to downplay significant threats such as breast cancer and blood clots, which research has linked to these treatments. Effective health policy should prioritize proven facts and personalized care, rather than sensational claims that might lead to increased prescriptions and potentially preventable cancers.